

ASX Announcement

Preliminary Final Report - Reporting Adjustments

Sydney, Australia, 29 September 2023: Imugene Limited (ASX:IMU or the Company) advises that its Annual Report lodged concurrently on the ASX includes an adjustment not included in the Company's Appendix 4E: Preliminary Final Report released on 25 August 2023 (Preliminary Final Report).

The adjustment relates to IMU's Research and Development tax incentive receivable for the year ended 30 June 2023. An additional \$1.256 million has been accrued to adjust for the appropriate corporate tax rate increasing from 25% to 30% for the 2023 financial year.

The adjustment is approximately 10.4% of the reported trade and other receivables balance in 2023. The adjustment is not considered to be material in the context of the results or other information included in IMU's Preliminary Final Report. The adjustment is outlined in the table below:

	Preliminary Final Report	Change	Annual Report
	\$'000	\$'000	\$'000
Consolidated statement of profit or loss and other comprehensive income			
Other income:			
R&D tax incentive	10,521	1,256	11,777
Consolidated statement of financial position			
Trade and other receivables	10,849	1,256	12,105

Release approved by the Company Secretary on behalf of the Board.



For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer, multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and



resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.